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J Sex MedBackground: Brain sexual differentiation is a process that results from the effects of sex steroids on the
developing brain. Evidence shows that epigenetics plays a main role in the formation of enduring brain sex
differences and that the estrogen receptor a (ESR1) is one of the implicated genes.
Aim: To analyze whether the methylation of region III (RIII) of the ESR1 promoter is involved in the biological
basis of gender dysphoria.
Methods: We carried out a prospective study of the CpG methylation profile of RIII (1,188 to 790 bp) of
the ESR1 promoter using bisulfite genomic sequencing in a cisgender population (10 men and 10 women) and
in a transgender population (10 trans men and 10 trans women), before and after 6 months of gender-affirming
hormone treatment. Cisgender and transgender populations were matched by geographical origin, age, and sex.
DNAs were treated with bisulfite, amplified, cloned, and sequenced. At least 10 clones per individual from
independent polymerase chain reactions were sequenced. The analysis of 671 bisulfite sequences was carried out
with the QUMA (QUantification tool for Methylation Analysis) program.
Outcomes: The main outcome of this study was RIII analysis using bisulfite genomic sequencing.
Results: We found sex differences in RIII methylation profiles in cisgender and transgender populations.
Cismen showed a higher methylation degree than ciswomen at CpG sites 297, 306, 509, and at the total
fragment (P  .003, P  .026, P  .001, P  .006). Transmen showed a lower methylation level than trans
women at sites 306, 372, and at the total fragment (P  .0001, P  .018, P  .0107). Before the hormone
treatment, transmen showed the lowest methylation level with respect to cisgender and transgender populations,
whereas transwomen reached an intermediate methylation level between both the cisgender groups. After the
hormone treatment, transmen showed a statistically significant methylation increase, whereas transwomen
showed a non-significant methylation decrease. After the hormone treatment, the RIII methylation differences
between transmen and transwomen disappeared, and both transgender groups reached an intermediate
methylation level between both the cisgender groups.
Clinical Implications: Clinical implications in the hormonal treatment of trans people.
Strengths & Limitations: Increasing the number of regions analyzed in the ESR1 promoter and increasing the
number of tissues analyzed would provide a better understanding of the variation in the methylation pattern.
Conclusions: Our data showed sex differences in RIII methylation patterns in cisgender and transgender
populations before the hormone treatment. Furthermore, before the hormone treatment, transwomen and
transmen showed a characteristic methylation profile, different from both the cisgender groups. But thebruary 28, 2020. Accepted May 27, 2020.
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2 Fernández et alhormonal treatment modified RIII methylation in trans populations, which are now more similar to their gender.
Therefore, our results suggest that the methylation of RIII could be involved in gender dysphoria. Fernández R,
Ramírez K, Gómez-Gil E, et al. Gender-Affirming Hormone Therapy Modifies the CpG Methylation Pattern
of the ESR1 Gene Promoter After Six Months of Treatment in Transmen. J Sex Med 2020;XX:XXXeXXX.
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Gonadal steroids, testosterone and estradiol, are involved in
the development of the sexual phenotype by binding to specific
nuclear receptors (androgen receptor [AR] and estrogen receptors
[ERs], a and b) that are transcription factors.1 The receptor-
ligand complex moves to the nucleus and triggers sex-specific
gene expression. The presumptive route for brain masculiniza-
tion is the direct induction of gene expression via activation of
ERs a and b and the AR.2e4
Masculinization of the brain is largely induced by estradiol
synthetized from testosterone by the aromatase enzyme CYP19,
matching the karyotype, gonads, and genitals to the gender.5 In
contrast, the lack of early exposure to testosterone in women al-
lows the development of a feminized brain, in concordance with
their feminized phenotype (karyotype, gonads, and genitals).
In mammals, brain sex differences occur in some brain areas
such as the preoptic area (POA), the bed nucleus of the stria
terminalis, and also the hypothalamic nuclei.6,7 In newborn male
rodents, aromatized estradiol in the POA from testicular an-
drogens induces major changes, which are generated in the first
days after birth, affecting the volume and number of cells, and
remain until adulthood.8 Estradiol promotes neuritic growth, as
well as changes in synapse and dendritic spine formation in
several regions of the central nervous system. Synapses and
afferences toward the arcuate nucleus decrease when the ovaries
are removed and are restored by supplying estradiol again.9
Estradiol increases the size of cell bodies and the volume of the
hypothalamic ventromedial nucleus10,11 as well as synapse den-
sity in this region.10ethylation degree (%) at each CpG site and from the total
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97.9 89.4 95.7
(þ6m) 86.8 97.4 94.7In addition, the membrane organization in these neurons is
also sexually dimorphic, and the administration of high-dose
prenatal estradiol to female rats irreversibly erases this sexual
difference.12
But circulating steroid hormones also serve as precursors to the
synthesis of neurosteroids.13 The steroid precursors readily enter
the brain, and new neurosteroids are synthesized that modulate
neural excitability by rapid non-genomic actions.14 Generally,
neurosteroids modulate brain excitability primarily by interaction
with neural membrane receptors and ion channels, principally
GABA-A receptors.15
A mechanism of action of peripheral sex steroids is the
modification of the activity of DNA methyltransferase enzymes
by modifying DNA methylation in the C5 site of CpG di-
nucleotides, masculinizing behaviors and brain structures.16 The
neuronal DNA methylome is highly modifiable by exogenous
steroids, with rapid changes in “de novo” methylation causing
variations in the expression of genes associated with neural
plasticity.17 This mechanism can significantly affect the processes
of cerebral sexual differentiation, so that the prescription of
hormonal therapies for gender reassignment treatment can act as
an epigenetic factor, modifying the methylome and consequently
changing the expression of genes, such as those of AR and ER a
and b.
Transgender women, also known as transwomen or male-to-
female transsexuals, are born with male genitalia and are
assigned as male at birth, but they have a feminine gender. On
the contrary, transgender men, also known as transmen or
female-to-male transsexuals, are born with female genitalia andfragment in the ESR1 promoter, in the cisgender and transgender
ormone treatment
306 372 405 509 Total
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82.6 70.2 53.2 89.4 82.6
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Table 2. P-values of Fisher's exact test and the Mann-Whitney U-test for all groups and all ESR1 promoter CpG sites and total fragments
CpGs Groups Cismen Transwomen Transwomen (þ6m) Transmen Transmen (þ6m)
111 Ciswomen 0.509 0.048* 0.725 0.085 1.000
Cismen – 0.230 1.000 0.260 0.315
Transwomen – 0.248 0.687 0.023*
Transwomen (þ6m) – 0.361 0.564
Transmen – 0.050*
Transmen (þ6m) –
203 Ciswomen 0.734 0.791 1.000 1.000 0.176
Cismen – 0.374 1.000 0.753 0.177
Transwomen – 0.597 0.802 0.020*
Transwomen (þ6m) – 1.000 0.201
Transmen – 0.105
Transmen (þ6m) –
297 Ciswomen 0.003† 0.028* 0.071 0.071 0.040*
Cismen – 0.211 0.612 0.612 0.419
Transwomen – 0.733 0.733 1.000
Transwomen (þ6m) – 1.000 1.000
Transmen – 1.000
Transmen (þ6m) –
306 Ciswomen 0.026* 0.037* 0.652 0.330 0.749
Cismen – 1.000 0.121 0.0001‡ 0.002†
Transwomen – 0.172 0.0001‡ 0.002†
Transwomen (þ6m) – 0.050* 0.315
Transmen – 0.407
Transmen (þ6m) –
372 Cis women 0.347 0.251 0.058 0.005† 0.249
Cismen – 0.683 0.203 0.011* 0.011*
Transwomen – 0.248 0.018* 0.002†
Transwomen (þ6m) – 0.478 0.0003‡
Transmen – 0.0001‡
Transmen (þ6m) –
405 Ciswomen 0.823 0.231 0.798 0.022* 0.501
Cismen – 0.218 0.832 0.006* 0.588
Transwomen – 0.465 0.076 0.637
Transwomen (þ6m) – 0.053 0.837
Transmen – 0.034*
Transmen (þ6m) –
509 Ciswomen 0.001† 0.310 0.781 0.232 1.000
Cismen – 0.003† 0.004† 0.051 0.0003‡
Transwomen – 0.633 0.626 0.325
Transwomen (þ6m) – 0.552 0.814
Transmen – 0.217
Transmen (þ6m) –
Total Fisher's exact test Cis women 0.006* 0.339 0.716 0.2613 0.360
Cismen – 0.015* 0.020* 0.0001‡ 0.044*
Trans women – 0.692 0.0107* 0.932
Transwomen (þ6m) – 0.1030 0.590
Transmen – 0.019*
Transmen (þ6m) –
Total Mann-Whitney U-test Ciswomen 0.066 0.935 0.902 0.131 0.513
Cismen – 0.006* 0.095 0.0003‡ 0.154
Transwomen – 0.881 0.021* 0.325
(continued)
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Table 2. Continued
CpGs Groups Cismen Transwomen Transwomen (þ6m) Transmen Transmen (þ6m)
Transwomen (þ6m) – 0.121 0.670
Transmen – 0.020*
Transmen (þ6m) –
*Significant differences at level P  .05.
†Significant differences at level P  .005.
‡Significant differences at level P  .0005.
4 Fernández et alare assigned as females at birth, but they have a masculine
gender. Transgender people generally experience gender
dysphoria because the incongruence between their biological sex
and their inner gender identity,18,19 and for this reason, they
often search for hormone therapy, with or without surgery, to
align their physical and psychologic features with their inner
gender. On the other hand, people without gender incongruence
are classified as cisgender.20
The origin of gender incongruence seems to be multifactorial. It
might be related to neurodevelopmental processes of the brain19,21
probably as a consequence of a genetic vulnerability22e32 that
implicates variations in the nuclear receptor's sensitivity to their
ligand. In our previous studies,31 we first proposed a hypothetic
genetic model based on ERa, ERb, and AR allele combinations.
We suggested that different allele combinations could modulate
the sensitivity and therefore the efficiency of the ER to the ligand,
and thus, different ERa, ERb, and AR allele combinations may
play a significant role in brain masculinization.
DNA methylation in gender incongruence has not been
studied in depth, although research shows that it is involved in
the development and plasticity of mammalian brains.33 Evidence
has suggested that changes in the methylation of the ESR1
promoter could participate in the conformation of cerebral
dimorphism in specific brain areas34 because DNA methylation
adds stability to transcription repression when it is located at the
promoter sites of mammalian genes.35 DNA methylation can
alter chromatin structures and prevents the access of transcription
factors to gene promoterse36 regulating gene expression. On the
other hand, there is evidence showing that postnatal experiences
have a lasting effect on adult ERa expression.37,38
The influence of gender-affirming hormone treatment on the
global methylation level of ESR1, ESR2, and AR genes was
studied by Aranda et al.39 They conducted a prospective obser-
vational study in 12 transwomen and 6 transmen, comparing the
degree of global methylation before and after hormonal treat-
ment, finding an increase in the overall methylation of the ESR1
in transmen, after 6 and 12 months of hormonal treatment. But
they did not contrast cisgender and transgender populations, nor
did they examine the CpG methylation profiles using bisulfite
genomic sequencing, obtaining overall methylation levels. Other
studies have shown that promoters are capable of being activated
or inhibited in particular physiological situations or by the action
of exogenous compounds with estrogenic activity.40,41In this article, we study the CpG methylation pattern of re-
gion III (RIII) of the ESR1 promoter.42 RIII corresponds to a
tissue-dependent and differentially methylated region (T-DMR)
as described by Maekawa et al.43 It is distant from the tran-
scription start site (1,188 to 790 bp), and its methylation is
strongly associated with downregulation of ESR1 expression.
The analysis of RIII methylation was performed in a popu-
lation of transmen and transwomen, before and after 6 months of
gender-affirming hormone treatment, and they were compared
with a cisgender population with the same geographical origin,
sex and age, with the following objectives: (i) to find out if there
are methylation patterns associated with cisgender and trans-
gender variants, which will provide us with information about
the possible function of methylation in the process of sexual
differentiation of the brain, which would support our previous
hypothesis that estrogen and the ESR1 participate in brain sexual
differentiation in our species and (ii) to establish whether the
hormonal treatment of gender affirmation produces any modi-
fication on the methylation pattern of the ESR1 in blood.METHODS AND MATERIALS
We carried out a prospective analysis of the CpG methylation
profile of RIII (1,188 to 790 bp) of the ESR1 promoter,42
using bisulfite genomic sequencing, in a cisgender and in a
transgender Spanish population, before and after 6 months of
gender-affirming hormone treatment. To carry out the investi-
gation, the steps followed are as follows.Study Design and Subjects
The population analyzed was 10 transgender men (ie, natal
female individuals transitioning to male individulas), 10 trans-
gender women (ie, natal male individuals transitioning to female
individuals), 10 cisgender men, and 10 cisgender women. The
transgender population was recruited, diagnosed, and treated
with gender-affirming hormone treatment at the Gender Unit of
the Clínic Hospital of Barcelona (Spain) from July 2015 to
November 2018. The inclusion criteria for transgender groups
were the presence of gender incongruence as per International
Classification of Diseases, 11th Revision,44 identification with
the other gender (male or female), the early presence of onset of
gender non-conformity (before puberty); to be erotically attrac-
ted to persons with the same anatomical sex, and to have no priorJ Sex Med 2020;-:1e12
Figure 1. Global RIII methylation degree in the cisgender and transgender populations before and after gender-affirming hormone
treatment. Cismen showed a higher RIII methylation degree than ciswomen, and it was the highest methylation degree. Transwomen
initially showed an intermediate RIII methylation level between both cisgender populations, and after 6 months of treatment, they showed a
slight demethylation and still showed an intermediate RIII methylation degree between both cisgender populations. Transmen showed the
lowest RIII methylation level before the hormone treatment, but after 6 months of hormone treatment, they showed an important RIII
methylation increase reaching an intermediate level between ciswomen and cismen. The Bonferroni correction estimated the significant
differences at level P  .007. * Significant differences at level P  .05. *** Significant differences at level P  .005. RIII ¼ region III.
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development. Sexual orientation was established by asking which
partner (a man, a woman, both, or neither) they would prefer or
feel attraction to if they were completely free to choose and their
body did not interfere.
The exclusion criteria were head trauma, neurologic and
hormonal disorder, major medical condition (we excluded
those with a history of cardiovascular disease, diabetes, or
positive HIV), and a history of alcohol and/or drug abuse. No
one had concomitant treatment. To dismiss the presence of
psychiatric disorders and substance abuse of all participants,
the Mini-International Neuropsychiatric Interview45 was
administered.
The cisgender population was selected from the biobank
generated from the Pizarra country census (Pizarra, Málaga, Spain)
matching by geographical origin, sex, and age. The main charac-
teristics of the Pizarra census were described in a previous study46:
individuals were excluded if they had been hospitalized for any
reason in the 4 weeks before the evaluation, if they were pregnant,
or had a severe medical or psychiatric disorder (these exclusion
criteria were also applied to the transgender population).
Furthermore, Pizarra participants were asked if they had acute or
chronic medical conditions (history of cardiovascular disease,
diabetes, or positive HIV), a history of alcohol and/or drug abuse,
and if they identified themselves as a woman or a man.
Written informed consent was obtained from the transgender
group after a full explanation of the procedures. The PizarraJ Sex Med 2020;-:1e12participants signed informed consent for the donation of the
samples to the biobank of the Regional Universitario Hospital of
Málaga (previously Carlos Haya Hospital) for medical research
studies. The study was approved by the Ethics Committee of the
Clinic Hospital (Barcelona) and the Regional Universitario
Hospital (Málaga).
Transgender and cisgender groups were matched by age and
sex. The age range of the transgender group at the beginning of
the investigation was 18e38 years (mean 24.5) and 18e40 years
(mean 24.8) for the cisgender group.Gender-Affirming Hormonal Treatment in the
Transgender Population
The hormonal treatment in the transmen population consisted
of intramuscular administration of testosterone ciclopentilpro-
pionato (cipionato) (250 mg every 21e28 days), whereas the
transwomen population received estradiol valerate (2e4 mg/
day), associated with acetate of cyproterone (50 mg/day).Bisulfite Genomic Sequencing
Genomic DNAs from the transgender population were
extracted from 5-ml tetrasodium ethylenediaminetetraacetate
dihydrate blood samples using the DNeasy Blood & Tissue
Kit from Qiagen (Madrid, Spain) following the manufacturer's
protocol. The DNAs were extracted twice before starting
gender-affirming hormone treatment and after 6 months of
treatment. Subsequently, 200e500 ng DNAs from
Figure 2. Comparative RIII methylation analysis between cismen, ciswomen, transwomen, and transmen. The analyzed RIII fragment has
7 CpGs in sites 111, 203, 297, 306, 372, 405, and 509. When the methylation degree was compared between ciswomen and cismen,
statistically significant differences were found at the CpG sites 297, 306, and 509. Furthermore, the methylation degree of the total
fragment was statistically significant between the 2 groups. The methylation degree was higher in cismen than in ciswomen in all sta-
tistically significant CpGs and in the total fragment. When comparing transwomen and transmen, statistically significant differences were
found at sites 306 and 372 and at the total fragment. In both statistically significant sites (306 and 372), and also at the total fragment,
the methylation degree was higher in transwomen than in transmen.The Bonferroni correction estimated the significant differences at level
P  .007. * Significant differences at level P  .05. ** Significant differences at level P  .005. *** Significant differences at level P  .0005.
RIII ¼ region III.
6 Fernández et altransgender and cisgender populations were treated with
bisulfite using the MethylCode Bisulfite Conversion Kit
(Invitrogen, Madrid, Spain) following the manufacturer's
protocol. In this reaction, unmethylated cytosine is trans-
formed into uracil, and 5-methylcytsine remains non-reactive,
allowing the analysis of the methylated DNA profiles with
high resolution when bisulphite conversion is followed by
sequencing.47Figure 3. Comparative RIII methylation analysis in transgender pop
significant differences were found at any CpG site, nor in the total frag
group before, vs after, the hormone treatment. And statistically signifi
total fragment when we compared methylation levels in the transmen
the hormonal treatment, the methylation degree at the 111 CpG site de
was a significant increase. The Bonferroni correction estimated the sign
P  .05. *** Significant differences at level P  .0005. RIII ¼ region IRIII Amplification
We amplified by polymerase chain reaction (PCR) a 568-bp
fragment of the ESR1 promoter, described as RIII by Asada
et al42 using 4 ml of the methylated DNA.The PCR conditions
were 95C for 10 min and 40 cycles of 94C for 30 s, 55C for
30 s, and 72C for 1 min, with a final extension at 72C for
10 min. Primers were described by Asada et al.42 The resulting
products were examined in a 1.8% agarose gel electrophoresisulations before, vs after, the hormonal treatment. No statistically
ment when comparing the methylation profiles in the transwomen
cant differences were found at sites 111, 372, 405, and also at the
population before, vs after, 6 months of hormone treatment. After
creased, whereas at sites 372, 405 and at the total fragment, there
ificant differences at level P  .007. * Significant differences at level
II.
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Figure 4. Representation of the CpG methylation degree in RIII, in cisgender populations vs transwomen, before and after the hormonal
treatment. Before treatment, transwomen vs ciswomen showed a statistically higher methylation degree at sites 111, 297, and 306. With
respect to cismen, transwomen showed a statistically lower methylation degree at site 509 and also at the total fragment. After 6 months
of hormone treatment, the methylation analysis between transwomen and ciswomen showed no statistically significant differences at any
site, whereas with respect to cismen, it showed a statistically lower methylation degree at 509 site and at the total fragment. Overall, the
transwomen population showed a slight methylation decrease after the hormonal treatment, but it remained at an intermediate
methylation level between both cisgender groups. The Bonferroni correction estimated the significant differences at level P  .007. *
Significant differences at level P  .05. ** Significant differences at level P  .005. RIII ¼ region III.
Figure 5. Representation of the CpG methylation pattern in RIII, in cisgender populations vs transmen, before and after the hormonal
treatment. Before the hormone treatment, and with respect to cismen, the transmen showed a statistically lower methylation degree at
CpG sites 306, 372, and 405 and also at the total RIII fragment. With respect to ciswomen, the transmen population also showed a lower
methylation degree statistically significant at CpG sites 372 and 405. After the hormone treatment, the transmen population showed, with
respect to cismen, a significantly lower methylation degree at CpG sites 306, 509, and also at the total fragment. In site 372, the
methylation degree was higher in transmen than in cismen.With respect to ciswomen, there were statistically significant differences only at
site 297. The Bonferroni correction estimated the significant differences at level P  .007. * Significant differences at level P  .05.
** Significant differences at level P  .005. *** Significant differences at level P  .0005. RIII ¼ region III.
J Sex Med 2020;-:1e12
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8 Fernández et aland purified using a QIAquick Gel Extraction Kit (Qiagen,
Madrid, Spain).Cloning and Sequencing
Amplified PCR products (3 ml) were cloned with a T&A
Cloning Vector plasmid (Yeastern Biotech Co, Ltd, Madrid,
Spain), following the commercial indications. The trans-
formation was subsequently performed in competent Escherichia
coli cells (Yeastern Biotech Co, Ltd, Madrid, Spain) and plated
with solid Lysogeny broth agar medium at 37C overnight. The
white colonies were selected, and the size of the insert was
examined by PCR. Subsequently, the clones with the correct size
(748 bp ¼ 568 bp fragment þ 180 pb vector) were grown in
1.5 ml Lysogeny broth agar medium at 37C overnight, and the
fragments were isolated using the miniprep technique following
the manufacturer's protocol (QIAprep Spin Miniprep Kit, Qia-
gen, Madrid, Spain).
To define the methylation profiles, at least 10 clones per in-
dividual, from independent PCRs, were sequenced using a
3130xl Genetic Analyzer (Applied Biosystems, Madrid, Spain).Statistical Analysis
To align, visualize, and quantify the methylated CpGs from
671 bisulfite sequences, we used the QUMA (QUantification
tool for Methylation Analysis) software http://quma.cdb.riken.
jp.48 Statistically significant differences between CpG sites were
evaluated using the Fisher's exact test because it is suitable for
binary data in unpaired samples. The 2  2 table is used to
compare methylation effects in CpG sites in 2 groups.49 Sig-
nificance between groups was evaluated by the Mann-Whitney
U-test because it can be used for the comparison of a non-
normally distributed parameter in 2 unpaired samples (http://
quma.cdb.riken.jp/).49
The conditions of exclusion of low-quality DNA sequences
suggested by QUMA software were 5 bases as the maximum
limit of CpGs without conversion, 95% as the minimum limit of
CpGs with conversion, 10 bases as the maximum limit of
alignment defects, and 90% as the minimum limit of percentage
of identity. We highlighted results from the analysis that reached
statistical significance based on P < .05 and also with a more
stringent Bonferroni-corrected P threshold (P < .05/7 ¼ .007).
The CpGs passing the more stringent Bonferroni-corrected P
were considered our primary findings.RESULTS
RIII has 7 CpGs in sites 111, 203, 297, 306, 372, 405, and
509. The methylation degrees at the 7 CpG sites and also from
the total fragment in cisgender and transgender populations,
before and after gender-affirming hormone treatment, are shown
in Table 1. The P values of Fisher's exact tests and Mann-
Whitney U-tests are shown in Table 2.a) Comparative methylation analysis in ciswomen vs cismen:
The methylation degree was statistically significantly higher
in cismen than in ciswomen and passed the Bonferroni
correction at the CpG sites 297 (P  .003) and 509
(P  .001) and also at the total fragment (P  .006)
(Tables 1 and 2, Figures 1 and 2).
b) Comparative methylation analysis in transwomen vs trans-
men before gender-affirming hormone treatment: The
methylation degree was statistically significantly higher in
transwomen than in transmen and passed the Bonferroni
correction at the CpG site 306 (P  .0001) but did not pass
the Bonferroni correction at the total fragment (P  .0107)
(Tables 1 and 2, Figures 1 and 2).
c) Comparative methylation analysis in transwomen before, vs
after, the hormonal treatment: No statistically significant
differences were found at any CpG site, nor at the total
fragment, in the methylation pattern comparing transwomen
before vs after the hormone treatment (Tables 1 and 2;
Figures 1 and 3).
d) Comparative methylation analysis in transmen before, vs af-
ter, the hormonal treatment: After the hormone treatment,
the transmen population showed a statistically significant
increase that passed the Bonferroni correction at the CpG site
372 (P  .0001) (Tables 1 and 2; Figures 1 and 3).
e) Comparative methylation analysis between the transwomen
and cisgender population, before and after the hormone
treatment: Before treatment, transwomen vs ciswomen
showed a statistically (P < .05) higher methylation degree at
sites 111 (P  .048), 297 (P  .028), and 306 (P  .037).
With respect to cismen, transwomen showed a statistically
lower methylation degree at site 509 (P  .003) that passed
the Bonferroni correction (Tables 1 and 2, Figures 1 and 4).
After 6 months of gender-affirming hormone treatment, the
methylation analysis between transwomen and cismen
showed a statistically lower methylation degree at 509 CpG
site (P  .004) (Tables 1 and 2; Figure 4). Overall, the
transwomen population showed a slight methylation decrease
after the hormonal treatment, which still remains at an in-
termediate methylation level between ciswomen and cismen
populations.
f) Comparative methylation analysis between the transmen and
cisgender population, before and after the hormone treat-
ment: Before the hormonal treatment, the transmen popu-
lation showed statistically significant differences with respect
to both cisgender populations. The methylation degree was
higher in cismen than in transmen and passed the Bonferroni
correction at CpG sites 306 (P  .0001) and 405 (P  .006)
and at the total fragment (P  .0001) (Tables 1 and 2;
Figures 1 and 5). With respect to ciswomen, the methylation
degree was statistically higher in ciswomen than in transmen
at CpG sites 372 (P  .005) (Tables 1 and 2; Figures 1 and
5). After the hormone treatment, the comparative analysis
between transmen and cismen showed statistically significant
differences at CpG sites 306 (P  .002) and 509 (P  .0003)J Sex Med 2020;-:1e12
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was lower in transmen at both CpG sites, 306 and 509.DISCUSSION
Our data support the existence of a sexually dimorphic pattern
of RIII methylation in blood and in cisgender and transgender
populations before hormonal treatment. RIII was defined as a T-
DMR by Maekawa et al43 demonstrating that ESR1 expression is
regulated by DNA methylation at this T-DMR, rather than by
DNA methylation of regions RI or RII, at the promoter region.
RIII was more densely methylated in cismen than in cis-
women and in transwomen more than in transmen. This RIII
methylation pattern in blood is observed in all CpG sites with
statistical significance that passed the Bonferroni correction, and
also in global RIII methylation.
Before the hormone treatment, the transgender population
showed a characteristic methylation profile in blood that is
different from cismen and ciswomen. Transwomen showed an
intermediate methylation level between both the cisgender
groups, higher than ciswomen but lower than cismen. However,
transmen showed the lowest RIII methylation degree of the study
(lower than transgender groups, before or after the hormone
treatment, and also lower than both the cisgender groups).
But after 6 months of hormone treatment, transmen and
transwomen reached an intermediate methylation level between
ciswomen and cismen. Transmen showed a global RIII
methylation increase that was very strong at 372 and 405 CpG
sites but inverse at site 111.
Consequently, the data obtained indicate that estradiol treat-
ment did not produce significant changes in RIII methylation in
transwomen, unlike testosterone that induced a significant in-
crease in RIII methylation in transmen. These different results
imply the existence of different physiological mechanisms of
exogenous estradiol and testosterone.
Our data are consistent with previous methylation studies of
the POA of the rat.50,51 This area has sexual dimorphism because
men show higher levels of methylation and lower levels of ESR1
expression from day 2 postnatal to adulthood. This implies a
sexually different expression of the ESR1, which arises in early
postnatal development and remains until adulthood, influencing
the hormonal sensitivity of the ERa receptor. Therefore, an
understanding of the effects of the exogenous steroid on RIII
methylation could be a relevant aspect in understanding sexual
differentiation.
In addition, Schwarz et al52 found that in rats, males show
higher methylation levels at the ERa promoter than females;
female adult rats showed almost 30% less methylation than
males. Moreover, Auger et al53 correlated the highest methyl-
ation degree in males with a reduction in the ERa protein. In
humans, the demethylation of the ESR1 promoter also correlates
with its enhanced expression.54 Thereby, according toJ Sex Med 2020;-:1e12methylation and expression studies, in humans and other species,
there is a sexually different methylation pattern of the ESR1.
According to our data, cismen showed the highest RIII
methylation level, and based on expression studies,43 it should
correspond to the lowest expression of the ESR1 gene. In the case
of transmen, before the hormone treatment, they showed the
lowest RIII methylation level that should be related to the highest
ESR1 gene expression. Nevertheless, transwomen showed an in-
termediate RIII methylation degree in blood that is between cis-
men and ciswomen and that should correspond to an intermediate
ESR1 gene expression, higher than cismen but lower than cis-
women. Therefore, before hormone treatment, the transgender
population showed a RIII methylation degree that did not match
with either of the cisgender groups, and after 6 months of treat-
ment, both transgender groups reached an intermediate RIII
methylation level between ciswomen and cismen, more similar to
their gender but that was still characteristic of those groups.
To our knowledge, there is only 1 study about ESR1
methylation in transgender individuals undergoing hormone
treatment. Aranda et al39 compared a transsexual population
before and after hormonal treatment. In this respect, our data are
consistent with this work because they also found an increase in
the methylation degree of the ESR1 gene in transmen and found
no statistical significance in transwomen.
On the other hand, these data are also consistent with our
previous genetic data on the participation of the ESR1 gene in
the genetic basis of gender dysphoria.30,31 Here, we propose that
variations in RIII methylation are related to the process of
masculinization of the brain and, therefore, to the etiology of
gender incongruence.Limitations of the Study
This work presents some limitations. In the first place, given
the limited number of individuals analyzed, the inclusion of a
larger sample would be necessary to achieve greater statistical
power.
Undoubtedly, a longer follow-up study (at 12 and 18 months
of treatment) would provide important additional information,
although Colizzi et al55 advised that metabolic changes are more
noticeable during the first 12 months of hormonal treatment.
In addition, increasing the number of regions analyzed in the
ESR1 promoter and increasing the number of tissues analyzed
would provide a better understanding of the variation in the
methylation pattern.
Moreover, the cisgender population was asked whether they
identified themselves as men or women, but the question about
other no binary identities was not asked. Nevertheless, the proba-
bility of a non-binary identification in our sample is extremely low.
Another limitation of our work is the lack of a study of the
ESR1 gene expression that proves that changes at RIII methyl-
ation cause a decrease in the ESR1 protein.
10 Fernández et alThe strength of our study is that it is the first to analyze the
methylation pattern of RIII in the ESR1 promoter in a trans-
gender population using bisulfite genomic sequencing.
CONCLUSIONS
The present study showed (i) that in both cisgender and
transgender populations, men and women had different RIII
methylation patterns in blood; (ii) that before the hormonal
treatment, both transgender groups showed a characteristic
RIII methylation profile in blood, which did not match any of
the cisgender groups; (iii) that in transmen, the treatment with
exogenous testosterone acted as an epigenetic factor that
significantly modified the RIII methylation pattern in blood,
although it still did not coincide with any of the cisgender
population patterns. In this context, the increase in RIII
methylation with the consequent decrease in ESR1 expression
in transmen supports that the ERa receptor must have an
important role in the mechanisms of masculinization; (iv) that
in transwomen, the estrogen treatment did not produce sig-
nificant changes in the RIII methylation pattern; and (v) as a
consequence, the different effects of hormonal treatment on the
RIII methylation are of clinical interest in the follow-up of
transgender men.
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